BioMarin's Q3 Net Income Hit By Lower Product Sales

BioMarin Pharmaceutical Inc BMRN reported a 14% Y/Y decrease in Q3 revenue to $408.7 million, missing the consensus estimate of $435.32 million.
The decline was attributable to lower sales from Kuvan, Aldurazyme, Vimizim, and Naglazyme, partially offset by higher revenues from Palynziq and Brineura.
Kuvan sales decreased 45% to $67.7 million, primarily due to generic competition.
Vimizim and Naglazyme sales dipped 7% each to $136.9 million and $71.2 million, respectively, primarily driven by the timing of orders from Europe and the Middle East.
Sales from Palynziq increased 32% at $60.7 million, primarily due to revenues from more patients in the U.S. achieving maintenance dosing and new patients initiating therapy.
Brineura sales were up 30% at $32.9 million due to new patients initiating therapy driven by EMEA and North America growth.
BioMarin posted an EPS loss of $(0.20), compared to earnings of $4.01, beating the consensus loss of $(0.25).
Lower product revenues resulted in a decline in adjusted income from $98.7 million to $33.5 million.
Guidance: BioMarin revised its FY21 guidance with sales of $1.82 billion - $1.88 billion (consensus $1.85 billion), compared to the earlier outlook of $1.79 billion - $1.88 billion.
It forecasts an adjusted income of $215 million - $255 million, compared to previous guidance of $190 million - $240 million.
Related: Stifel Upgrades This Pharma Stock On Prospective FDA Approval For Dwarfism Drug.
Price Action: BMRN shares closed at $71.72 on Wednesday.

Market News and Data brought to you by Benzinga APIs

Comments

Earnings Calendar

Never Miss Important Catalysts

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga